Global Blood Therapeutics Inc buy stratec
Start price
14.12.17
/
50%
€36.49
Target price
04.11.21
€83.14
Performance (%)
-7.61%
End price
05.11.21
€33.71
Summary
This prediction ended on 05.11.21 with a price of €33.71. With a performance of -7.61%, the BUY prediction by stratec finished with a loss. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Global Blood Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | 1.085% | -0.846% | 12.464% | 58.472% |
| iShares Nasdaq 100 | -1.665% | -3.306% | 1.502% | 84.473% |
| iShares Nikkei 225® | 3.863% | 6.308% | 22.272% | 56.185% |
| iShares S&P 500 | 0.111% | -1.337% | 1.101% | 58.320% |
Comments by stratec for this prediction
In the thread Global Blood Therapeutics Inc diskutieren
stratec stimmt der Buy-Einschätzung von klostergang zu
stratec stimmt am 14.12.2017 der Buy-Einschätzung von klostergang mit dem Kursziel 42,5$ zu.
Überschrift: Global Blood Th., mit Produktentwicklung für SCD und Hypoxämie#
14.12.2017 Global Blood Therapeutics (NASDAQ:GBT) price raised to $70 (83% upside) from $51 by Needham citing expected positive results from the Phase 3 HOPE study of voxelotor in sickle cell disease.
The FDA granted the company's lead candidate voxelotor Breakthrough Therapy for the treatment of sickle cell disease. It has a similar designation in Europe. Voxelotor is an oral once-daily therapy that works by increasing hemoglobin's affinity for oxygen.
Kursziel geändert auf 83,14
In the thread Trading Global Blood Therapeutics Inc
Die von stratec gewählte maximale Laufzeit wurde überschritten